Clal Biotechnology Industries Ltd. (CBI.TA)
ILA 35.6
(-0.84%)
ILA 35.6
(-0.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 104 Thousand ILS | -20.12% |
| 2022 | 12.87 Million ILS | -83.38% |
| 2021 | 77.46 Million ILS | 15.33% |
| 2020 | 67.17 Million ILS | -0.97% |
| 2019 | 67.83 Million ILS | -15.83% |
| 2018 | 80.58 Million ILS | -14.56% |
| 2017 | 94.32 Million ILS | -23.39% |
| 2016 | 123.11 Million ILS | -10.03% |
| 2015 | 136.84 Million ILS | -11.7% |
| 2014 | 154.97 Million ILS | 4.94% |
| 2013 | 147.68 Million ILS | 55.1% |
| 2012 | 95.21 Million ILS | -17.05% |
| 2011 | 114.78 Million ILS | 6.69% |
| 2010 | 107.59 Million ILS | 33.1% |
| 2009 | 80.83 Million ILS | 10.7% |
| 2008 | 73.02 Million ILS | 44.96% |
| 2007 | 50.37 Million ILS | 100.67% |
| 2006 | 25.1 Million ILS | -0.14% |
| 2005 | 25.13 Million ILS | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 3 Million ILS | -9.13% |
| 2023 Q4 | 15.39 Million ILS | 0.0% |
| 2023 Q2 | 3 Million ILS | 0.0% |
| 2023 Q3 | 15.39 Million ILS | 412.11% |
| 2023 FY | 10.28 Million ILS | -20.12% |
| 2022 Q2 | 18.51 Million ILS | 0.5% |
| 2022 Q3 | 3.82 Million ILS | -79.36% |
| 2022 FY | 12.87 Million ILS | -83.38% |
| 2022 Q4 | 3.3 Million ILS | -13.42% |
| 2022 Q1 | 18.42 Million ILS | -3.06% |
| 2021 Q2 | 19.56 Million ILS | 4.16% |
| 2021 FY | 77.46 Million ILS | 15.33% |
| 2021 Q4 | 19 Million ILS | -5.56% |
| 2021 Q3 | 20.12 Million ILS | 2.86% |
| 2021 Q1 | 18.78 Million ILS | 6.01% |
| 2020 Q4 | 17.71 Million ILS | 0.83% |
| 2020 FY | 67.17 Million ILS | -0.97% |
| 2020 Q1 | 15.23 Million ILS | -28.25% |
| 2020 Q2 | 16.65 Million ILS | 9.29% |
| 2020 Q3 | 17.57 Million ILS | 5.53% |
| 2019 Q4 | 21.23 Million ILS | 36.87% |
| 2019 Q2 | 12.66 Million ILS | -31.22% |
| 2019 FY | 67.83 Million ILS | -15.83% |
| 2019 Q1 | 18.41 Million ILS | 27.98% |
| 2019 Q3 | 15.51 Million ILS | 22.44% |
| 2018 Q3 | 20.23 Million ILS | -13.81% |
| 2018 Q1 | 25.06 Million ILS | 14.92% |
| 2018 FY | 80.58 Million ILS | -14.56% |
| 2018 Q4 | 14.39 Million ILS | -28.88% |
| 2018 Q2 | 23.47 Million ILS | -6.32% |
| 2017 Q4 | 21.8 Million ILS | 9.4% |
| 2017 Q2 | 24.56 Million ILS | -12.33% |
| 2017 Q1 | 28.01 Million ILS | 6.05% |
| 2017 FY | 94.32 Million ILS | -23.39% |
| 2017 Q3 | 19.93 Million ILS | -18.84% |
| 2016 Q2 | 37.75 Million ILS | 38.22% |
| 2016 Q1 | 27.31 Million ILS | -19.7% |
| 2016 Q3 | 31.62 Million ILS | -16.24% |
| 2016 FY | 123.11 Million ILS | -10.03% |
| 2016 Q4 | 26.41 Million ILS | -16.47% |
| 2015 Q3 | 25.19 Million ILS | -26.14% |
| 2015 FY | 136.84 Million ILS | -11.7% |
| 2015 Q2 | 34.11 Million ILS | -21.59% |
| 2015 Q4 | 34.01 Million ILS | 35.0% |
| 2015 Q1 | 43.5 Million ILS | -6.28% |
| 2014 Q2 | 34.17 Million ILS | -30.22% |
| 2014 Q1 | 48.97 Million ILS | 19.23% |
| 2014 FY | 154.97 Million ILS | 4.94% |
| 2014 Q4 | 46.42 Million ILS | 23.43% |
| 2014 Q3 | 37.61 Million ILS | 10.06% |
| 2013 Q2 | 38.89 Million ILS | 38.31% |
| 2013 Q3 | 40.94 Million ILS | 5.28% |
| 2013 FY | 147.68 Million ILS | 55.1% |
| 2013 Q4 | 41.07 Million ILS | 0.3% |
| 2013 Q1 | 28.12 Million ILS | 13.93% |
| 2012 Q3 | 24.28 Million ILS | 20.92% |
| 2012 Q4 | 24.68 Million ILS | 1.63% |
| 2012 FY | 95.21 Million ILS | -17.05% |
| 2012 Q1 | 26.16 Million ILS | 0.0% |
| 2012 Q2 | 20.08 Million ILS | -23.23% |
| 2011 FY | 114.78 Million ILS | 6.69% |
| 2010 FY | 107.59 Million ILS | 33.1% |
| 2009 FY | 80.83 Million ILS | 10.7% |
| 2008 FY | 73.02 Million ILS | 44.96% |
| 2007 FY | 50.37 Million ILS | 100.67% |
| 2006 FY | 25.1 Million ILS | -0.14% |
| 2005 FY | 25.13 Million ILS | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Matricelf Ltd | 11.78 Million ILA | 99.118% |